Hengrui Medicine intends to launch a global offering of 224.5 million H shares from May 15 to 20, 2025, with a share price range of HK$41.45 to HK$44.05 per share and a lot size of 200 shares. The company anticipates listing on the Hong Kong Stock Exchange on May 23. To accommodate international demand, Hengrui Medicine reserves the right to exercise an over-allotment option. As a pioneering pharmaceutical firm, Hengrui Medicine dedicated 29.4% of its 2024 budget to R&D, and the sales share of innovative drugs has steadily risen each year. From 2022 to 2024, the company's revenue surged to RMB 21.3 billion, RMB 22.8 billion, and RMB 28 billion, respectively, accompanied by a consistent increase in net profit margin. The projected net proceeds from this fundraising campaign are estimated to be between HK$9.458 billion and HK$12.528 billion, funds that will be allocated to R&D, production, and the development of R&D facilities. Hengrui Medicine has already secured agreements with cornerstone investors for a combined subscription of US$533 million.